134
Participants
Start Date
September 30, 2013
Primary Completion Date
October 24, 2014
Study Completion Date
August 31, 2017
Alectinib
Participants will receive alectinib as described in the arm descriptions.
Richmond University Medical Center; Pharmacy Department, Staten Island
Memorial Sloan-Kettering Cancer Center, Commack
Roswell Park Cancer Inst., Buffalo
University of Pittsburgh Cancer Pavillion, Pittsburgh
Penn State Hershey Cancer Institute, Hershey
St. Luke's Hospital; Pharmacy Department, Bethlehem
Fox Chase Cancer Center, Philadelphia
Virginia Cancer Specialists, PC, Fairfax
Wake Forest University Health Sciences, Winston-Salem
MUSC Hollings Cancer Center, Charleston
Florida Hospital Cancer Inst, Orlando
UF Health Orlando, Orlando
Lynn Regional Cancer Center West, Boca Raton
H. Lee Moffitt Cancer Center and Research Inst., Tampa
University of Alabama at Birmingham, Birmingham
Center for Biomedical Research LLC, Knoxville
The Ohio State University Comprehensive Cancer Center, Columbus
Gabrail Cancer Center, Canton
St. Joseph Mercy Hospital; Cancer Care Center., Ann Arbor
Wayne State Uni ; Karmanos Cancer Center, Detroit
University of Wisconsin, Madison
Monroe Medical Associates; Ingalls Memorial Hosp, Harvey
University of Illinois Cancer Center, Chicago
Texas Oncology-Baylor Sammons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
Univ of Colorado Canc Ctr, Aurora
National Jewish Health, Denver
UCLA, Los Angeles
UCSD Moores Cancer Center, La Jolla
Loma Linda Cancer Center, Loma Linda
University of California Irvine, Irvine
Providence Portland Med Ctr, Portland
Oregon Health & Science Uni, Portland
Swedish Cancer Inst., Seattle
Massachussets General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Can Ins, Boston
Newton-Wellesley Hospital, Newton
Hackensack Univ Med Ctr, Hackensack
Cross Cancer Institute, Edmonton
Lakeridge Health Oshawa; Oncology, Oshawa
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal
Hoffmann-La Roche
INDUSTRY